Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
22.54%
Operating Margin
17.98%
Net Margin
13.03%
Efficiency Metrics
Revenue per Expense Ratio
1.22
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
22.14%
Income Tax Rate
21.68%
EPS
18.0500000000
Balance Sheet Analysis
Current Ratio
3.57
Cash Ratio
1.55
Working Capital
$11.79B
Debt to Equity
0.33
Debt to Assets
19.66%
Equity Ratio
59.25%
Cash Flow Analysis
Operating Cash Flow Ratio
20.49%
Free Cash Flow Ratio
14.11%
CapEx to Revenue
6.38%
Dividends Paid
$514.53M
Stock Buybacks
$1.55B
Total Shareholder Returns
$2.07B
Cash Position Change
49.11%
Key Takeaways (2023 FY)
Revenue declined by 16.37813045416%, indicating potential market challenges
Increased dividend payments by 1.28%
Detailed Growth Metrics
Core Performance
Revenue
-16.38%
Net Income
-40.52%
EPS
-37.50%
Operating Income
-40.67%
Operational Efficiency
R&D Expenses
0.00%
SG&A Expenses
-20.69%
Operating Cash Flow
-29.39%
Free Cash Flow
-39.71%
Balance Sheet Health
Assets
8.81%
Debt
3.85%
Book Value per Share
18.74%
Inventory
2.28%
Shareholder Returns
Dividends per Share
1.28%
Shares Outstanding
-4.79%
Long Term Trends
3Y Revenue/Share
109.21%
5Y Revenue/Share
75.12%
3Y Dividend/Share
27.03%
5Y Dividend/Share
34.05%